GLP-3 R 15mg
$189.99
GLP-3 R 15mg
Retatrutide
CAS: 2381609-35-2
Retatrutide (GLP-3 R) 15mg — the standard Clav stack supply. Triple GLP-1/GIP/Glucagon receptor agonist. Phase 2: −28.7% body weight at 48 weeks.
For research purposes only. Not intended for human use.
Triple-Agonist: GLP-1R + GIPR + GcgR
Retatrutide activates three receptors simultaneously — the most receptor coverage of any GLP compound in research. GLP-1R drives hypothalamic appetite suppression and satiety. GIPR enhances insulin sensitivity and adipocyte lipid metabolism. GcgR activates hepatic beta-oxidation and brown adipose thermogenesis — an active fat-burning mechanism absent in semaglutide and tirzepatide. This third receptor is the differentiator that produced Phase 2 data of −28.7% at 48 weeks, the highest result ever recorded for a GLP compound.
Phase 2: −28.7% at 48 weeks
Retatrutide Phase 2 trial at 8mg/week produced −28.7% body weight reduction at 48 weeks. The trajectory had not plateaued at trial end, suggesting continued loss with extended protocols. This exceeds tirzepatide's best Phase 3 result (−20.9%) and semaglutide's best (−14.9%).
GcgR — The Third Mechanism
Glucagon receptor engagement drives hepatic fat oxidation and brown adipose thermogenesis. Unlike GLP-1/GIP which primarily suppress appetite, GcgR activation causes the body to burn fat directly — raising resting energy expenditure. This is the mechanism responsible for Retatrutide's clinical advantage.
Dose Escalation Protocol
Phase 2 used a 3-step escalation: 2mg/week (weeks 1-4) → 4mg/week (weeks 5-8) → 8mg/week (week 9+). The escalation minimizes GI side effects during adaptation. Running BPC-157 concurrently provides gut protection throughout.
Specifications
Research FAQ
Why does the Clav stack use Retatrutide over tirzepatide?
Retatrutide's triple-agonist profile (GLP-1 + GIP + Glucagon) produced −28.7% at 48 weeks vs tirzepatide's −20.9%. The glucagon receptor engagement drives hepatic fat oxidation and thermogenesis — mechanisms absent in dual agonists.
What is the reconstitution protocol for Retatrutide 15mg?
Add 5mL bacteriostatic water to the 15mg vial for a 3mg/mL concentration. Inject slowly along the vial wall — do not shake. Store reconstituted at 2-8°C for up to 6 weeks.
Should I run BPC-157 alongside Retatrutide?
Yes — BPC-157 is considered essential with any GLP protocol. Retatrutide delays gastric emptying and alters gut motility. BPC-157's gastroprotective mechanism (NO system upregulation) supports gut health throughout dose escalation.
Related Products
GLP-3 R 10mg
Retatrutide (GLP-3 R) 10mg — starter supply for triple GLP-1/GIP/Glucagon receptor agonist research. The entry-level Clav stack compound. Phase 2: −28.7% body weight at 48 weeks. >98% purity, HPLC tested, lyophilized.
CAS: 2381609-35-2
